Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3924-3933

  Inoue, Kinya ^a   Torimura, Takuji ^a,b   Nakamura, Toru ^a   Iwamoto, Hideki ^a   Masuda, Hiroshi ^a   Abe, Mitsuhiko ^a   Hashimoto, Osamu ^a   Koga, Hironori ^a   Ueno, Takato ^a   Yano, Hirohisa ^a   Sata, Michio ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CANCER; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PIPERIDINES; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863977102     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2041     Document Type: Article

References (33)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 2009;27:833-5.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Trail PA, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
5. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72. (Pubitemid 46202316)
6. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34. (Pubitemid 43338212)
7. Kirsch M, Schackert G, Black PM. Metastasis and angiogenesis. Cancer Treat Res 2004;117:285-304.
8. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta 2009;1793:293-308.
9. Kudo M. Early detection and characterization of hepatocellular carcinoma: value of imaging multistep human hepatocarcinogenesis. Intervirology 2006;49:64-9. (Pubitemid 41318178)
10. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27:854-61. (Pubitemid 27454829)
11. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77. (Pubitemid 28299987)
12. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Sujaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-91. (Pubitemid 28422048)
13. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24:1809-19. (Pubitemid 40462784)
14. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46. (Pubitemid 35154440)
15. Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, et al. HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. J Hepatol 2008;49:955-64.
16. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011;62:4645-55.
17. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004;3:1041-8. (Pubitemid 39295001)
18. Yano H, Maruiwa M, Murakami T, Fukuda K, Ito Y, Sugihara S, et al. A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol Jpn 1988;38:953-66.
19. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M, Kojiro M. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 1993;18:320-7. (Pubitemid 23225103)
20. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001;20:2768-78. (Pubitemid 32938560)
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28. (Pubitemid 24324921)
22. Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Ashida M, et al. Interferon-a/b and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo. PLoS One 2011;6:e19618.
23. Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007;6:1932-41. (Pubitemid 47052483)
24. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
25. Giannelli G, Azzariti A, Sgarra C, Porcelli L, Antonaci S, Paradiso A. ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol 2006;71:479-85. (Pubitemid 43077082)
26. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small inframe deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64:9101-4. (Pubitemid 39665524)
27. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000;19:6122-9. (Pubitemid 32059462)
28. Matsuo, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003;2:557-61.
29. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
30. Natale RB, Badkin D, Govinndan R, Sleckman GB, Rizvi NA, Capo A, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-9.
31. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
32. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
33. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009;361:1018-20.